US EditionPublished • loading... • Updated
Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China
Pfizer China gains exclusive rights to commercialize Sciwind's Ecnoglutide in Mainland China with up to $495M in milestones; drug targets type 2 diabetes and obesity.
- On Feb. 24, 2026, Hangzhou Sciwind Biosciences announced a strategic commercialization collaboration with Pfizer China, granting Pfizer exclusive rights to market Ecnoglutide injection in Mainland China.
- Policy attention to metabolic health — including the Healthy China Initiative — has driven regulatory progress, with China's NMPA recently approving Ecnoglutide for adult type 2 diabetes.
- Clinical data show Chinese clinical trial participants achieved 15.1% placebo-adjusted weight loss, 92.8% clinically meaningful weight loss, and over 80% with HbA1c below 7.0%, while Sciwind Biosciences remains the Marketing Authorization Holder and is eligible for $495 million in potential milestone payments.
- Pfizer said the collaboration advances Pfizer's global metabolic strategy and integrates Sciwind Biosciences' innovation with Pfizer China's commercialization to accelerate patient access in China.
- Looking ahead, Sciwind Biosciences said the partnership supports its metabolic strategy, with Pfizer China committed to continued investment for adults with type 2 diabetes and weight management.
Insights by Ground AI
31 Articles
31 Articles
keenesentinel.com+25 Reposted by 25 other sources
Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China
HANGZHOU, China, Feb. 24, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased GLP–1 receptor agonist. Under the agreement, Pfizer will obtain exclusive…
- U.S. Pfizer entered into a rights acquisition agreement...
Coverage Details
Total News Sources31
Leaning Left5Leaning Right7Center7Last UpdatedBias Distribution37% Center, 37% Right
Bias Distribution
- 37% of the sources are Center, 37% of the sources lean Right
37% Right
L 26%
C 37%
R 37%
Factuality
To view factuality data please Upgrade to Premium
